BioCentriq is a strategic, New Jersey-based CDMO for cell and gene therapy, focusing on all stages of process development and clinical manufacturing.
With more than 70 scientists, engineers, analysts, and manufacturing specialists, the company has established quality systems and the infrastructure required to support the release of autologous and allogeneic drug products. BioCentriq also specializes in viral vector process development and manufacturing with expertise in a variety of cell and vector types.
Our newly constructed state-of-the art facilities include five ISO-7 certified GMP manufacturing suites which can be configured to suit the needs of your program, a fully equipped process development laboratory, quality control and analytical method development laboratories, and training facilities.
Therapy developers choose BioCentriq because of our extraordinary level of expertise and experience in process development and MS&T and our ability to dedicate the right resources to ensure smooth and effective tech transfer and GMP readiness for IND-enabling studies and Phase 1 clinical manufacturing. We are extremely sensitive to the challenges faced by growing biotech companies and work alongside our client teams to help them move from bench scale to clinical production.
We also operate the only McKinsey-owned Digital Capability Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences.